Scarica l'app Stockscreener
14.58
6.54%
-1.02
Dopo l'orario di chiusura:
14.71
0.13
+0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.60
Aprire:
$15.63
Volume 24 ore:
1.01M
Relative Volume:
0.94
Capitalizzazione di mercato:
$728.33M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.9512
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-5.26%
1M Prestazione:
+24.83%
6M Prestazione:
+69.34%
1 anno Prestazione:
+1.32%
Intervallo 1D:
$14.48
$15.63
Intervallo di 1 settimana:
$14.48
$15.97
Portata 52W:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Nome
Kalvista Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 999-0075
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta KALV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
14.58 | 779.28M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-12-18 | Iniziato | BofA Securities | Buy |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-29 | Iniziato | SVB Leerink | Outperform |
| 2019-03-20 | Iniziato | Needham | Buy |
| 2018-10-30 | Iniziato | Jefferies | Buy |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Iniziato | BTIG Research | Buy |
Mostra tutto
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
EMA’s CHMP adopts five orphans - biocentury.com
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com India
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest
Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):